Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

Luis Paz‐Ares; Filippo de Marinis; Mircea Dediu; Michael Thomas; Jean-Louis Pujol; Paolo Bidoli; Olivier Molinier; Tarini Prasad Sahoo; Eckart Laack; Martin Reck; J. Corral; Symantha Melemed; William J. John; Nadia Chouaki; Annamaria H. Zimmermann; Carla Visseren‐Grul; Cesare Gridelli

doi:10.1016/s1470-2045(12)70063-3

Keywords

PemetrexedMedicineInternal medicineOncologyLung cancerClinical endpointMaintenance therapyPerformance statusPopulationPlaceboInduction chemotherapyChemotherapyCisplatinSurgeryRandomized controlled trialPathology

Affiliated Institutions

Related Publications

PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Filippo de Marinis , Mircea Dediu +14 more

Purpose In the phase III PARAMOUNT trial, pemetrexed continuation maintenance therapy reduced the risk of disease progression versus placebo (hazard ratio [HR], 0.62; 95% CI, 0....

2013 Journal of Clinical Oncology 626 citations

IFCT-GFPC-1101 trial: A multicenter phase III assessing a maintenance strategy determined by response to induction chemotherapy compared to continuation maintenance with pemetrexed in patients (pts) with advanced non-squamous (NSQ) NSCLC.

M. Pérol , Clarisse Audigier-Valette , Olivier Molinier +17 more

9003 Background: Benefit coming from maintenance treatment appears greater for switch maintenance in pts with disease stabilization (SD) while it might be larger for continuatio...

2017 Journal of Clinical Oncology 6 citations

Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes

Pascale Tomasini , Fabrice Barlési , Céline Mascaux +1 more

Non-small cell lung cancer (NSCLC) is still the leading cause of cancer-related death, and the treatment of advanced NSCLC relies on systemic treatments. During the last decade,...

2016 Therapeutic Advances in Medical Oncology 63 citations

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Howard West , Michael McCleod , Maen Hussein +17 more

Atezolizumab (a monoclonal antibody against PD-L1), which restores anticancer immunity, improved overall survival in patients with previously treated non-small-cell lung cancer ...

2019 The Lancet Oncology 1597 citations

Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

Roy S. Herbst , Giuseppe Giaccone , Joan H. Schiller +14 more

Purpose Preclinical studies indicate that gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington, DE), an orally active epidermal growth factor receptor tyrosine kinase inhibitor, m...

2004 Journal of Clinical Oncology 1714 citations

Publication Info

Year: 2012
Type: article
Volume: 13
Issue: 3
Pages: 247-255
Citations: 605
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

605

OpenAlex

Cite This

APA Style

                            
                                
                                    Luis Paz‐Ares, 
                                
                                    Filippo de Marinis, 
                                
                                    Mircea Dediu
                                
                                et al.
                            
                            (2012). 
                            Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. 
                            The Lancet Oncology
                            , 13
                            (3)
                            , 247-255.
                            https://doi.org/10.1016/s1470-2045(12)70063-3
                        

Identifiers

DOI: 10.1016/s1470-2045(12)70063-3